# Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment

> **NCT04396223** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 26 (estimated)

## Conditions studied

- Gestational Trophoblastic Neoplasias (GTN)

## Interventions

- **DRUG:** Avelumab Injection
- **DRUG:** Methotrexate 1 GM Injection

## Key facts

- **NCT ID:** NCT04396223
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-12
- **Primary completion:** 2025-04-12
- **Final completion:** 2028-10-12
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04396223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04396223, "Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04396223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*